The Virtual Investor “What This Means” segment featuring Outlook Therapeutics is now available here.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.

Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ... for ...

Macular degeneration is a devastating eye condition that affects around 200 million people worldwide, primarily those over ...

This systematic review was therefore performed to assess the efficacy and safety of available treatments for RVO as reported in randomized controlled trials (RCTs), and to assess the feasibility ...

A recent study that compared 2 anti-vascular endothelial growth factor drugs for treating diabetic macular edema (DME) found that brolucizumab (Beovu ... University of Miami, Miami. The current ...